Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Columbia Licenses Novel 3-D Organ and Tumor Segmentation Software to Varian Medical Systems

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
Allows for more precise and efficient planning and monitoring of cancer treatment.

Columbia University has signed a licensing agreement with Varian Medical Systems for novel imaging software that facilitates 3-D segmentation, the process by which anatomical structures in medical images are distinguished from one another—an important step in the precise planning of cancer surgery and radiation treatments.

“Organ- and tumor-specific segmentation is fundamental for proper radiation treatment planning and follow-up in cancer patients,” said Lawrence Schwartz, MD, professor and chair of the Department of Radiology, Columbia University Medical Center, who has extensive experience in both conventional and novel imaging techniques. “Our algorithms have been developed in response to the growing demand for quantitative imaging techniques that provide more accurate organ/tumor delineation and tumor response criteria. At the Computational Image Analysis Laboratory, led by Binsheng Zhao, DSc, professor of clinical radiology, we have incorporated advanced methodologies to address these needs. Columbia is pleased to have established a relationship with Varian, a manufacturer of treatment devices.”

Three-D segmentation of CT and MR images provides a reliable way to identify organs such as the liver, spleen, and kidneys. Determining organ and tumor contours and volumes (including those of primary and metastatic tumors) before, during, and after treatment can be challenging. Accurate and efficient characterization of these diverse structures is necessary to enable noninvasive assessments in clinical practice and clinical trials, as well as in radiation treatment planning.

“Modern radiation treatment planning requires careful delineation of the targeted tissue, as well as the critical structures to be avoided,” said Jeff Amacker, senior director of clinical solutions at Varian. “We hope that our collaborative efforts with Columbia University Medical Center’s radiology department will lead to improved patient care by providing new tools and automation for the precise planning of radiation treatments.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Two Treatments for Retinitis Pigmentosa Move Closer to Clinical Trials
One treatment involves skin-derived induced pluripotent stem (iPS) cell grafts, the other gene therapy.
Friday, December 21, 2012
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!